Geode Capital Management, LLC Nymox Pharmaceutical Corp Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$0.95 - $2.1 $50 - $111	-53 Reduced 0.1%	50,678 $65,000
Q3 2021 Nov 12, 2021	BUY	$1.3 - $2.23 $11,811 - $20,261	9,086 Added 21.82%	50,731 $104,000
Q2 2021 Aug 13, 2021	SELL	$1.46 - $2.48 $381,658 - $648,296	-261,410 Reduced 86.26%	41,645 $65,000
Q1 2021 May 12, 2021	BUY	$2.22 - $3.39 $7,241 - $11,058	3,262 Added 1.09%	303,055 $672,000
Q4 2020 Feb 12, 2021	BUY	$1.84 - $2.83 $4,704 - $7,236	2,557 Added 0.86%	299,793 $743,000
Q3 2020 Nov 13, 2020	BUY	$2.3 - $3.66 $28,533 - $45,405	12,406 Added 4.36%	297,236 $731,000
Q2 2020 Aug 13, 2020	BUY	$2.1 - $4.6 $510,799 - $1.12 Million	243,238 Added 584.82%	284,830 $1.01 Million
Q1 2020 May 14, 2020	BUY	$1.69 - $3.88 $26,059 - $59,829	15,420 Added 58.92%	41,592 $97,000
Q3 2019 Nov 12, 2019	SELL	$1.41 - $2.12 $1,174 - $1,765	-833 Reduced 3.08%	26,172 $48,000
Q2 2019 Aug 14, 2019	SELL	$1.33 - $2.12 $162,724 - $259,379	-122,349 Reduced 81.92%	27,005 $39,000
Q1 2019 May 14, 2019	BUY	$1.57 - $2.71 $24,072 - $41,552	15,333 Added 11.44%	149,354 $294,000
Q4 2018 Feb 13, 2019	BUY	$1.31 - $2.53 $17,164 - $33,150	13,103 Added 10.84%	134,021 $175,000
Q3 2018 Nov 13, 2018	BUY	$2.46 - $3.7 $27,384 - $41,188	11,132 Added 10.14%	120,918 $297,000
Q2 2018 Aug 14, 2018	BUY	$3.12 - $4.33 $60,166 - $83,499	19,284 Added 21.31%	109,786 $368,000
Q1 2018 May 15, 2018	BUY	$3.09 - $4.43 $4,035 - $5,785	1,306 Added 1.46%	90,502 $382,000
Q4 2017 Feb 13, 2018	BUY	$3.29 - $4.06 $26,389 - $32,565	8,021 Added 9.88%	89,196 $294,000
Q3 2017 Nov 14, 2017	BUY	$3.36 - $4.02 $23,748 - $28,413	7,068 Added 9.54%	81,175 $310,000
Q2 2017 Aug 14, 2017	BUY	N/A	74,107	74,107 $326,000

Others Institutions Holding NYMX

# of Institutions

Shares Held

150K

Call Options Held

Put Options Held

View Full List

About NYMOX PHARMACEUTICAL CORP

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

More about NYMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account